Acute Kidney Injury in COVID-19 Patients: Pathogenesis, Clinical Characteristics, Therapy, and Mortality

• Published in: Diseases Vol. 10; no. 3; p. 53
• Main Authors: Chávez-Valencia, Venice, Orizaga-de-la-Cruz, Citlalli, Lagunas-Rangel, Francisco Alejandro
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19.08.2022; MDPI
• Subjects: ACE2; Acute renal failure; AKI; Androgens; Comorbidity; Coronaviruses; COVID-19; Creatinine; Cytokine storm; Glycoproteins; Health risk assessment; Hematuria; Infections; Kidneys; Lungs; molecular mechanisms; Mortality; Pathogenesis; Pathophysiology; Patients; Pneumonia; Proteins; Respiratory distress syndrome; Respiratory tract; Review; SARS-CoV-2; Sepsis; Severe acute respiratory syndrome coronavirus 2; Statistics; Urine; Viruses; China
• ISSN: 2079-9721; 2079-9721
• DOI: 10.3390/diseases10030053

Coronavirus disease 2019 (COVID-19) is a disease caused by infection with the SARS-CoV-2 virus and has represented one of the greatest challenges humanity has faced in recent years. The virus can infect a large number of organs, including the lungs and upper respiratory tract, brain, liver, kidneys, and intestines, among many others. Although the greatest damage occurs in the lungs, the kidneys are not exempt, and acute kidney injury (AKI) can occur in patients with COVID-19. Indeed, AKI is one of the most frequent and serious organic complications of COVID-19. The incidence of COVID-19 AKI varies widely, and the exact mechanisms of how the virus damages the kidney are still unknown. For this reason, the purpose of this review was to assess current findings on the pathogenesis, clinical features, therapy, and mortality of COVID-19 AKI.